Long-term benefit of afatinib combined with bevacizumab in a lung adenocarcinoma patient with a novel rare EGFR Q787L mutation
International Immunopharmacology · 2025
DOI: 10.1016/j.intimp.2025.114368 ↗Kurz gefasst
Fallbericht in der Zeitschrift International Immunopharmacology, 2025. Verfasst von Yingying Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary and Clinical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, No.6 Shuangyong Road, Nanning City 5…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Afatinib, Antineoplastic Combined Chemotherapy Protocols, Bevacizumab. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: The epidermal growth factor receptor (EGFR) is among the most frequently mutated genes in lung adenocarcinomas (LUAC). The combination of afatinib and bevacizumab has primarily been reported in LUAC cases exhibiting resistance to EGFR tyrosine kinase inhibitors (EGFR-TKI), particularly in classical variants such as EGFR exon 19 deletions and the L858R mutation in exon 21. However, the clinical efficacy of afatinib combined with bevacizumab in treating rare EGFR mutations remains underexplored. CASE PRESENTATION: We present a case of T4N0M0 stage IIIA LUAC in which disease progression occurred following tumor resection and subsequent chemotherapy combined with bevacizumab. Next-generation sequencing of peripheral blood identified a novel and rare EGFR exon 20 Q787L mutation. Maintenance therapy with icotinib, a first-generation EGFR-TKI, combined with bevacizumab was initiated, but the patient developed resistance to icotinib after 8 months. No drug availability variants or acquired resistance-related mutations were detected. Subsequently, maintenance therapy with oral afatinib plus bevacizumab was initiated, resulting in partial remission after 3 months. As of the most recent CT scan in November 2023, the patient has achieved a progression-free survival (PFS) of 56 months on afatinib plus bevacizumab maintenance therapy, representing the longest reported duration to date, with no severe side effects observed. CONCLUSION: Our findings suggest that the combination of afatinib and bevacizumab may offer long-term clinical benefits for LUAC patients harboring the novel and rare EGFR Q787L mutation. This case highlights a potential therapeutic strategy warranting further investigation in clinical studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary and Clinical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, No.6 Shuangyong Road, Nanning City 530021, PR China.
- Department of Pulmonary and Clinical Care Medicine, The First Affiliated Hospital of Guangxi Medical University, No.6 Shuangyong Road, Nanning City 530021, PR China. Electronic address: qiuliliang2009@163.com.
Zitieren
APA
Huang, Y., Qin, S., Tang, H., Jiang, J., & Liang, Q. (2025). Long-term benefit of afatinib combined with bevacizumab in a lung adenocarcinoma patient with a novel rare EGFR Q787L mutation. International Immunopharmacology. https://doi.org/10.1016/j.intimp.2025.114368
Vancouver
Huang Y, Qin S, Tang H, Jiang J, Liang Q. Long-term benefit of afatinib combined with bevacizumab in a lung adenocarcinoma patient with a novel rare EGFR Q787L mutation. International Immunopharmacology. 2025. doi:10.1016/j.intimp.2025.114368
BibTeX
@article{Huang2025,
author = {Huang, Yingying and Qin, Shouming and Tang, Haijuan and Jiang, Jing and Liang, Qiuli},
title = {Long-term benefit of afatinib combined with bevacizumab in a lung adenocarcinoma patient with a novel rare EGFR Q787L mutation},
journal = {International Immunopharmacology},
year = {2025},
doi = {10.1016/j.intimp.2025.114368}
}
EUVIMED